The Motley Fool Previous Page


Uncontrolled Crying Over AVANIR's Prescription Data?

http://www.fool.com/investing/high-growth/2011/05/10/uncontrolled-crying-over-avanirs-prescription-data.aspx

Brian Orelli
May 10, 2011

The nice thing about developing a drug for a disease without any other treatment options: You've got no competition.

The bad thing about developing a drug for a disease without any other treatment options: You've got to find the patients.

AVANIR Pharmaceuticals's (Nasdaq: AVNR  ) ┬áNue